YAP off, YAP on

How Vivace turns the YAP pathway off or on to treat cancer

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers. The newco emerged from stealth mode this summer after closing a $25 million Series B led by China-based Cenova Capital.

The Hippo-YAP pathway regulates cell growth and survival. Under normal conditions,

Read the full 665 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE